La Jolla Pharma +22.8% AH on positive trial results


La Jolla's (LJPC) Phase 2 trial of its GCS-100 chronic kidney disease drug "met its primary efficacy endpoint of a statistically significant improvement in kidney function." A 1.5 mg/m2 dose led to a statistically significant increase in estimated glomerular filtration rate relative to a a placebo. (PR)

Secondary endpoints were also achieved, and 117 out of 121 enrolled patients completed treatment.

La Jolla: "We hope to use these results as a platform for further investigation not only in chronic kidney disease but also in other diseases where tissue fibrosis plays a central role."

CC tomorrow at 8:30AM ET. Ahead of the CC, management is presenting at a Roth conference at 5:30PM ET today (webcast).

Wedbush launched coverage with an Outperform last month, arguing there was a "70% probability of a positive outcome" for the trial.

From other sites
Comments (1)
  • panchosfc
    , contributor
    Comments (44) | Send Message
     
    What is the potential for the platform? And for which other diseases with tissue fibrosis can be used?
    10 Mar 2014, 05:13 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs